OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 32.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 99,632 shares of the company's stock after buying an additional 24,463 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.14% of Kiniksa Pharmaceuticals worth $1,971,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of KNSA. Braidwell LP lifted its position in Kiniksa Pharmaceuticals by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after acquiring an additional 557,934 shares during the period. Millennium Management LLC lifted its position in Kiniksa Pharmaceuticals by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock valued at $15,422,000 after acquiring an additional 263,146 shares during the period. Dimensional Fund Advisors LP lifted its position in Kiniksa Pharmaceuticals by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after acquiring an additional 29,300 shares during the period. Geode Capital Management LLC lifted its position in Kiniksa Pharmaceuticals by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock valued at $9,744,000 after acquiring an additional 9,654 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Kiniksa Pharmaceuticals by 138.9% during the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after acquiring an additional 277,827 shares during the period. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Trading Up 1.5%

NASDAQ:KNSA traded up $0.38 on Friday, reaching $26.25. 541,889 shares of the stock traded hands, compared to its average volume of 484,855. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -187.49 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $17.38 and a 12 month high of $28.56. The company's fifty day simple moving average is $22.86 and its 200 day simple moving average is $21.35.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals's revenue was up 72.5% compared to the same quarter last year. During the same period last year, the business earned ($0.25) EPS. Equities analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target for the company. Finally, Wedbush restated an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $38.80.

Insider Transactions at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $20.48, for a total value of $245,760.00. Following the completion of the sale, the chief operating officer now directly owns 77,363 shares in the company, valued at $1,584,394.24. The trade was a 13.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Sanj K. Patel sold 2,872 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $27.03, for a total transaction of $77,630.16. Following the completion of the sale, the chief executive officer now owns 96,674 shares of the company's stock, valued at $2,613,098.22. This represents a 2.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 231,640 shares of company stock worth $5,669,136 over the last three months. 54.57% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.